Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:
“IPD analysis from checkmate 816 and checkmate 77T shows that periop IO strategy as in checkmate 77T had a benefit over neoadjuvant only approach in patients with pdl1 score<1% and non-path CR achievers.”
